Stay updated with breaking news from Patrick Baeuerle. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Crossbow Therapeutics, a biotech company developing a novel class of potent and precise antibody therapies to treat a broad range of cancers, has announced a $80 million Series A funding round.
Proprietary T-Bolt™ technology dramaticallybroadens the benefits of immunotherapy by targeting the entire universe of cancer antigens
FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!
CLN-619 is a MICA/B directed humanized IgG1 antibody being studied in a global Phase 1 clinical trial in patients with advanced solid tumors. Initial...
08.03.2022 - Five abstracts selected for poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2022 Data highlight progress on Cullinan Oncology’s pipeline of therapeutic candidates CLN-049 (Florentine), CLN-619 (MICA), ... Seite 1